News

Here you can find the latest TOPADUR news & events.

20.6.2022
News

Scientific Publication in Advanced Therapeutics

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.

Read more
19.5.2022
Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

Read more
7.4.2022
Press Release

TOPADUR in collaboration with USZ / UZH was awarded CHF 605k by Innosuisse

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

Read more
23.3.2022
Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

Read more
15.10.2021
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more
5.10.2021
Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

Read more

Do you need more information or references? Media contact

Investors

InvestorsNews & Events

About us

VisionLeadershipBoard of DirectorsHistoryResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer